The Utility of Acute‐Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia
Identifieur interne : 000823 ( Main/Exploration ); précédent : 000822; suivant : 000824The Utility of Acute‐Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia
Auteurs : S. J. Viitanen ; A. K. Lappalainen ; M. B. Christensen ; S. Sankari ; M. M. Rajam KiSource :
- Journal of Veterinary Internal Medicine [ 0891-6640 ] ; 2016.
Abstract
Acute‐phase proteins (
The aim of our study was to investigate the applicability of
Nineteen dogs diagnosed with
The study was conducted as a prospective longitudinal observational study. Serum
All measured
Serum
Url:
DOI: 10.1111/jvim.14631
PubMed: 28032360
PubMed Central: 5259651
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000640
- to stream Pmc, to step Curation: 000640
- to stream Pmc, to step Checkpoint: 000236
- to stream Ncbi, to step Merge: 000600
- to stream Ncbi, to step Curation: 000600
- to stream Ncbi, to step Checkpoint: 000600
- to stream Main, to step Merge: 000825
- to stream Main, to step Curation: 000823
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Utility of Acute‐Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia</title><author><name sortKey="Viitanen, S J" sort="Viitanen, S J" uniqKey="Viitanen S" first="S. J." last="Viitanen">S. J. Viitanen</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Lappalainen, A K" sort="Lappalainen, A K" uniqKey="Lappalainen A" first="A. K." last="Lappalainen">A. K. Lappalainen</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Christensen, M B" sort="Christensen, M B" uniqKey="Christensen M" first="M. B." last="Christensen">M. B. Christensen</name><affiliation><nlm:aff id="jvim14631-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Sankari, S" sort="Sankari, S" uniqKey="Sankari S" first="S." last="Sankari">S. Sankari</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Rajam Ki, M M" sort="Rajam Ki, M M" uniqKey="Rajam Ki M" first="M. M." last="Rajam Ki">M. M. Rajam Ki</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28032360</idno><idno type="pmc">5259651</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259651</idno><idno type="RBID">PMC:5259651</idno><idno type="doi">10.1111/jvim.14631</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000640</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000640</idno><idno type="wicri:Area/Pmc/Curation">000640</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000640</idno><idno type="wicri:Area/Pmc/Checkpoint">000236</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000236</idno><idno type="wicri:Area/Ncbi/Merge">000600</idno><idno type="wicri:Area/Ncbi/Curation">000600</idno><idno type="wicri:Area/Ncbi/Checkpoint">000600</idno><idno type="wicri:doubleKey">0891-6640:2016:Viitanen S:the:utility:of</idno><idno type="wicri:Area/Main/Merge">000825</idno><idno type="wicri:Area/Main/Curation">000823</idno><idno type="wicri:Area/Main/Exploration">000823</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Utility of Acute‐Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia</title><author><name sortKey="Viitanen, S J" sort="Viitanen, S J" uniqKey="Viitanen S" first="S. J." last="Viitanen">S. J. Viitanen</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Lappalainen, A K" sort="Lappalainen, A K" uniqKey="Lappalainen A" first="A. K." last="Lappalainen">A. K. Lappalainen</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Christensen, M B" sort="Christensen, M B" uniqKey="Christensen M" first="M. B." last="Christensen">M. B. Christensen</name><affiliation><nlm:aff id="jvim14631-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Sankari, S" sort="Sankari, S" uniqKey="Sankari S" first="S." last="Sankari">S. Sankari</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Rajam Ki, M M" sort="Rajam Ki, M M" uniqKey="Rajam Ki M" first="M. M." last="Rajam Ki">M. M. Rajam Ki</name><affiliation><nlm:aff id="jvim14631-aff-0001"></nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Veterinary Internal Medicine</title><idno type="ISSN">0891-6640</idno><idno type="eISSN">1939-1676</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="jvim14631-sec-0001"><title>Background</title><p>Acute‐phase proteins (<styled-content style="fixed-case">APP</styled-content>s) are sensitive markers of inflammation, and serum C‐reactive protein (<styled-content style="fixed-case">CRP</styled-content>) recently has been shown to be a useful diagnostic marker in dogs with bacterial pneumonia (<styled-content style="fixed-case">BP</styled-content>). In humans with community‐acquired pneumonia, <styled-content style="fixed-case">APP</styled-content>s also have great utility as follow‐up markers aiding in the assessment of treatment response.</p></sec><sec id="jvim14631-sec-0002"><title>Objectives</title><p>The aim of our study was to investigate the applicability of <styled-content style="fixed-case">APP</styled-content>s as markers of treatment response in dogs with <styled-content style="fixed-case">BP</styled-content>.</p></sec><sec id="jvim14631-sec-0003"><title>Animals</title><p>Nineteen dogs diagnosed with <styled-content style="fixed-case">BP</styled-content> and 64 healthy dogs.</p></sec><sec id="jvim14631-sec-0004"><title>Methods</title><p>The study was conducted as a prospective longitudinal observational study. Serum <styled-content style="fixed-case">CRP</styled-content>, serum amyloid A (<styled-content style="fixed-case">SAA</styled-content>), and haptoglobin concentrations were followed during a natural course of <styled-content style="fixed-case">BP</styled-content>. Normalization of serum <styled-content style="fixed-case">CRP</styled-content> was used to guide the duration of antibiotic treatment (treatment was stopped 5–7 days after <styled-content style="fixed-case">CRP</styled-content> normalized) in 8 of 17 dogs surviving to discharge; 9 of 17 dogs were treated according to conventional recommendations.</p></sec><sec id="jvim14631-sec-0005"><title>Results</title><p>All measured <styled-content style="fixed-case">APP</styled-content>s initially were significantly increased, but the magnitude of increase was not correlated to disease severity. C‐reactive protein and <styled-content style="fixed-case">SAA</styled-content> concentrations decreased rapidly after initiation of antimicrobial treatment. When normalization of serum <styled-content style="fixed-case">CRP</styled-content> was used to guide the duration of antibiotic treatment, treatment duration was significantly (<italic>P</italic> = .015) decreased without increasing the number of relapses.</p></sec><sec id="jvim14631-sec-0006"><title>Conclusions and Clinical Importance</title><p>Serum <styled-content style="fixed-case">CRP</styled-content> and <styled-content style="fixed-case">SAA</styled-content> reflected the recovery process well and therefore may be used as markers of treatment response. According to the results, the normalization of serum <styled-content style="fixed-case">CRP</styled-content> may be used to guide the duration of antibiotic treatment in dogs with <styled-content style="fixed-case">BP</styled-content>.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bonagura, Jd" uniqKey="Bonagura J">JD Bonagura</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, Lr" uniqKey="Johnson L">LR Johnson</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list></list><tree><noCountry><name sortKey="Christensen, M B" sort="Christensen, M B" uniqKey="Christensen M" first="M. B." last="Christensen">M. B. Christensen</name><name sortKey="Lappalainen, A K" sort="Lappalainen, A K" uniqKey="Lappalainen A" first="A. K." last="Lappalainen">A. K. Lappalainen</name><name sortKey="Rajam Ki, M M" sort="Rajam Ki, M M" uniqKey="Rajam Ki M" first="M. M." last="Rajam Ki">M. M. Rajam Ki</name><name sortKey="Sankari, S" sort="Sankari, S" uniqKey="Sankari S" first="S." last="Sankari">S. Sankari</name><name sortKey="Viitanen, S J" sort="Viitanen, S J" uniqKey="Viitanen S" first="S. J." last="Viitanen">S. J. Viitanen</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000823 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000823 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5259651
|texte= The Utility of Acute‐Phase Proteins in the Assessment of Treatment Response in Dogs With Bacterial Pneumonia
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28032360" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |